Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, U.S.A.
St. Louis University School of Medicine, St. Louis, Missouri, U.S.A.
Laryngoscope. 2020 Aug;130(8):1961-1966. doi: 10.1002/lary.28659. Epub 2020 Apr 15.
To determine the prognostic significance of smoking in human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) when considering American Joint Committee on Cancer eighth edition (AJCC-8) stage.
Retrospective cohort study.
Three hundred seventeen HPV-positive OPSCC patients with known AJCC-8 stage and smoking status (<10 or ≥10 pack-years) seen at a tertiary center from 1997 to 2017 were studied. We used the Kaplan-Meier method to compare 5-year overall survival (OS) by smoking status and by clinical AJCC-8 stage and smoking status combined. Hazard ratios (HRs) were estimated with Cox proportional hazard regression for the independent effects of smoking and AJCC-8 stage. We also studied pathologic stage and estimated the combined effects of smoking and clinical stage.
The ≥10 pack-years smokers had worse 5-year OS than <10 pack-years smokers (93.6%; 95% confidence interval (CI): 89.7-97.8 vs. 82.3%; 95% CI: 76.0%-89.1%). When stratified by AJCC-8 clinical stage, only stage I <10 pack-years smokers (98.7%; 95% CI: 96.3%-100.0%) had significantly better 5-year OS than their ≥10 pack-years (84.8%; 95% CI: 76.4%-94.1%) counterparts. In a multivariable analysis, ≥10 pack-years smoking was associated with increased hazard of death when adjusting for AJCC-8 clinical (HR: 2.52; 95% CI: 1.16-5.46) and pathologic (HR: 5.21; 95% CI: 1.47-18.5) stage. In both analyses, stage III patients demonstrated worse survival than stage I, and smoking had greater impact at lower stages.
Smoking is a negative prognosticator in HPV-positive OPSCC and interacts with AJCC-8 clinical stage. It is important to understand the impact of smoking in HPV-positive disease when considering treatment plans and deintensification trials.
2b Laryngoscope, 130: 1961-1966, 2020.
当考虑美国癌症联合委员会第八版(AJCC-8)分期时,确定吸烟在人乳头瘤病毒(HPV)阳性口咽鳞状细胞癌(OPSCC)中的预后意义。
回顾性队列研究。
对 1997 年至 2017 年间在一家三级中心就诊的 317 名已知 AJCC-8 分期和吸烟状况(<10 或≥10 包年)的 HPV 阳性 OPSCC 患者进行了研究。我们使用 Kaplan-Meier 方法比较了不同吸烟状态和临床 AJCC-8 分期的 5 年总生存率(OS),并结合吸烟状态和临床 AJCC-8 分期进行比较。使用 Cox 比例风险回归估计吸烟和 AJCC-8 分期的独立影响的风险比(HRs)。我们还研究了病理分期,并估计了吸烟和临床分期的综合影响。
10 包年以上的吸烟者的 5 年 OS 明显低于<10 包年的吸烟者(93.6%;95%置信区间[CI]:89.7-97.8%比 82.3%;95%CI:76.0%-89.1%)。按 AJCC-8 临床分期分层时,仅 I 期<10 包年的吸烟者(98.7%;95%CI:96.3%-100.0%)的 5 年 OS 显著优于≥10 包年的吸烟者(84.8%;95%CI:76.4%-94.1%)。在多变量分析中,在调整 AJCC-8 临床(HR:2.52;95%CI:1.16-5.46)和病理(HR:5.21;95%CI:1.47-18.5)分期后,≥10 包年的吸烟与死亡风险增加相关。在这两种分析中,III 期患者的生存率均低于 I 期,而吸烟对较低分期的影响更大。
吸烟是 HPV 阳性 OPSCC 的一个负预后因素,与 AJCC-8 临床分期相互作用。在考虑治疗计划和减毒试验时,了解 HPV 阳性疾病中吸烟的影响非常重要。
2b Laryngoscope, 130: 1961-1966, 2020.